Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis
Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administe...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/8/9/796 |
| _version_ | 1797519814117294080 |
|---|---|
| author | Audrey Monnin Amélie Vizeneux Nicolas Nagot Sabrina Eymard-Duvernay Nicolas Meda Mandisa Singata-Madliki Grace Ndeezi James Kashugyera Tumwine Chipepo Kankasa Ameena Goga Thorkild Tylleskär Philippe Van de Perre Jean-Pierre Molès |
| author_facet | Audrey Monnin Amélie Vizeneux Nicolas Nagot Sabrina Eymard-Duvernay Nicolas Meda Mandisa Singata-Madliki Grace Ndeezi James Kashugyera Tumwine Chipepo Kankasa Ameena Goga Thorkild Tylleskär Philippe Van de Perre Jean-Pierre Molès |
| author_sort | Audrey Monnin |
| collection | DOAJ |
| description | Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction. At week-50, telomere shortening was observed among 44.3% of CHEU, irrespective of the prophylactic treatment. Furthermore, this telomere shortening was neither associated with poor growth indicators nor neuropsychological outcomes at year-6, except for motor abilities (MABC test <i>n</i> = 127, β = −3.61, 95%CI: −7.08, −0.14; <i>p</i> = 0.04). Safety data on telomere shortening for infant HIV prophylaxis are scarce. Its association with reduced motor abilities deserves further attention among CHEU but also HIV-infected children receiving ARV treatment. |
| first_indexed | 2024-03-10T07:48:06Z |
| format | Article |
| id | doaj.art-2818a44236ce4250862e260e92046051 |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-10T07:48:06Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-2818a44236ce4250862e260e920460512023-11-22T12:30:13ZengMDPI AGChildren2227-90672021-09-018979610.3390/children8090796Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as ProphylaxisAudrey Monnin0Amélie Vizeneux1Nicolas Nagot2Sabrina Eymard-Duvernay3Nicolas Meda4Mandisa Singata-Madliki5Grace Ndeezi6James Kashugyera Tumwine7Chipepo Kankasa8Ameena Goga9Thorkild Tylleskär10Philippe Van de Perre11Jean-Pierre Molès12Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FrancePathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FrancePathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FrancePathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FranceCentre Muraz, Bobo-Dioulasso 01 P.O. Box 390, Burkina FasoEffective Care Research Unit, Cecilia Makiwane Hospital, University of Fort Hare, East London 5207, South AfricaDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala P.O. Box 317, UgandaDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala P.O. Box 317, UgandaDepartment of Paediatric and Child Health, University Teaching Hospital, University of Zambia School of Medicine, Lusaka P.O. Box 50110, ZambiaHIV Prevention Research Unit, South African Medical Research Council, Private Bag x385, Pretoria 0001, South AfricaCentre for International Health, Faculty of Medicine, University of Bergen, 5009 Bergen, NorwayPathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FrancePathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, FranceTelomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction. At week-50, telomere shortening was observed among 44.3% of CHEU, irrespective of the prophylactic treatment. Furthermore, this telomere shortening was neither associated with poor growth indicators nor neuropsychological outcomes at year-6, except for motor abilities (MABC test <i>n</i> = 127, β = −3.61, 95%CI: −7.08, −0.14; <i>p</i> = 0.04). Safety data on telomere shortening for infant HIV prophylaxis are scarce. Its association with reduced motor abilities deserves further attention among CHEU but also HIV-infected children receiving ARV treatment.https://www.mdpi.com/2227-9067/8/9/796HIVchildrenprophylaxistelomere shorteninggrowthneuropsychological development |
| spellingShingle | Audrey Monnin Amélie Vizeneux Nicolas Nagot Sabrina Eymard-Duvernay Nicolas Meda Mandisa Singata-Madliki Grace Ndeezi James Kashugyera Tumwine Chipepo Kankasa Ameena Goga Thorkild Tylleskär Philippe Van de Perre Jean-Pierre Molès Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis Children HIV children prophylaxis telomere shortening growth neuropsychological development |
| title | Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis |
| title_full | Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis |
| title_fullStr | Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis |
| title_full_unstemmed | Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis |
| title_short | Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis |
| title_sort | longitudinal follow up of blood telomere length in hiv exposed uninfected children having received one year of lopinavir ritonavir or lamivudine as prophylaxis |
| topic | HIV children prophylaxis telomere shortening growth neuropsychological development |
| url | https://www.mdpi.com/2227-9067/8/9/796 |
| work_keys_str_mv | AT audreymonnin longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT amelievizeneux longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT nicolasnagot longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT sabrinaeymardduvernay longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT nicolasmeda longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT mandisasingatamadliki longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT gracendeezi longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT jameskashugyeratumwine longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT chipepokankasa longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT ameenagoga longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT thorkildtylleskar longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT philippevandeperre longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis AT jeanpierremoles longitudinalfollowupofbloodtelomerelengthinhivexposeduninfectedchildrenhavingreceivedoneyearoflopinavirritonavirorlamivudineasprophylaxis |